Benzodiazepine use and brain amyloid load in nondemented older individuals a florbetapir PET study in the Multidomain Alzheimer Preventive Trial cohort

Abstract : It remains unclear whether benzodiazepines (BZDs) constitute a risk factor for Alzheimer's disease (AD). In this study, we investigated associations between chronic use of BZDs and brain amyloid load, a hallmark of AD, in 268 nondemented older individuals. F-florbetapir positron emission tomography scans were performed to assess amyloid load as measured by standardized uptake value ratios, which were compared between chronic BZD users and nonusers using adjusted multiple linear regressions. Short- versus long-acting BZDs were also considered in the analyses. Standardized uptake value ratios were significantly lower in BZD users (n = 47) than in nonusers (n = 221), independent of multiple adjustments. The effect was stronger for short-acting BZDs than for long-acting BZDs. This is the first large clinical study showing a reduced brain amyloid load in chronic BZD users, especially with short-acting BZDs. Our results do not support the view of BZD use as a risk factor for AD and instead support the involvement of pharmacological mechanisms related to neuronal hyperactivity, neuroinflammation, and sleep quality as potential targets for blocking amyloid accumulation.
Document type :
Journal articles
Complete list of metadatas

https://hal-univ-rennes1.archives-ouvertes.fr/hal-02307424
Contributor : Laurent Jonchère <>
Submitted on : Monday, October 7, 2019 - 3:47:57 PM
Last modification on : Thursday, October 31, 2019 - 9:20:03 AM

Identifiers

Citation

Thomas Desmidt, Julien Delrieu, Thibaud Lebouvier, Gabriel Robert, Renaud David, et al.. Benzodiazepine use and brain amyloid load in nondemented older individuals a florbetapir PET study in the Multidomain Alzheimer Preventive Trial cohort. Neurobiology of Aging, 2019, 84, pp.61-69. ⟨10.1016/j.neurobiolaging.2019.08.008⟩. ⟨hal-02307424⟩

Share

Metrics

Record views

21